Dimerix

Dimerix Free Cash Flow

The Free Cash Flow (FCF) of Dimerix (DXB.AX) as of Oct 19, 2026 is -51.81 M AUD. In the previous year, Free Cash Flow (FCF) was 39.03 M AUD — a change of -232.75% (lower).

Free Cash Flow

-51.81 MAUD

YoY

-232.75%

Last updated:

Free Cash Flow (FCF) of Dimerix is 2026 -51.81 M AUD. Free Cash Flow (FCF) of Dimerix was 2025 39.03 M AUD. It decreases by -232.75% lower compared to the previous year.

The Dimerix Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2019
-2.76 M AUD
Jan 1, 2020
-4.73 M AUD
Jan 1, 2021
-6.47 M AUD
Jan 1, 2022
-13.45 M AUD
Jan 1, 2023
-12.73 M AUD
Jan 1, 2024
-7.02 M AUD
Jan 1, 2025
39.03 M AUD
Jan 1, 2026
-51.81 M AUD
The Dimerix Free Cash Flow history
YEARFree Cash FlowYoY
-51.81 MAUD-232.75%
39.03 MAUD-656.02%
-7.02 MAUD-44.87%
-12.73 MAUD-5.31%
-13.45 MAUD+107.75%
-6.47 MAUD+36.81%
-4.73 MAUD+71.56%
-2.76 MAUD-14.59%
-3.23 MAUD+72.95%
-1.87 MAUD+35.18%
-1.38 MAUD+144.69%
-564,432.00AUD+0.70%
-560,534.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Free Cash Flow (FCF) of Dimerix is -51.81 M AUD in 2026.

Free Cash Flow (FCF) of Dimerix changed from 39.03 M AUD to -51.81 M AUD, representing a -232.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Dimerix since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Dimerix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Dimerix

All Key Metrics — Dimerix